Abstract
Many patients are excluded from HCV treatment due to psychiatric issues (PI) and substance abuse (SA). We sought to determine deferral rates and reasons for nontreatment, determine whether patients initially deferred for PI or SA subsequently received antiviral therapy, and compare treatment outcomes of these patients with patients who were not deferred. A retrospective analysis of 433 patients with HCV was conducted. Seventy-five percent of patients were deferred from treatment. Primary deferral reasons were PI (34.3%) and SA (33.6%). Characteristics were similar between eligible and ineligible treatment candidates. Of those initially deferred from therapy, over half returned for follow-up; however, only 13% eventually received treatment. Patients initially deferred for PI/SA but subsequently treated were less likely to complete treatment than patients without these comorbidities (48% vs. 13%). SVR was lower in patients with PI/SA compared to those without (26% vs. 47%). Deferral rates for PI/SA remain high, and these patients are rarely treated at subsequent clinic visits. When patients are deferred for PI/SA but later treated, they have significantly higher rates of not completing treatment and a trend toward lower SVR rates.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Seeff LB, Hoofnagle JH (2002) National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002. Hepatology 36:S3–S29
DiBesceglie AM, Hoofnagle JH (2002) Optimal therapy of hepatitis C. Hepatology 36:S121–S127
Fried MW, Shiffman ML, Reddy R, Smith C, Marinos G, Goncales FL, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975–982
Strader DB (2002) Understudied populations with hepatitis C. Hepatology 36:S226–S236
National Institutes of Health (1997) NIH Consensus Development Conference Panel Statement: management of hepatitis C. Hepatology 26:S2–S10
Fireman M, Indest DW, Blackwell A, Whitehead AJ, Hauser P (2005) Addressing tri-morbidity (hepatitis c, psychiatric disorders, and substance use): the importance of routine mental health screening as a component of a comanagement model of care. Clin Infect Dis 40:S286–S291
Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ (2002) Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 136:288–292
Shad J, Person J, Brann O, Moon S, Pockros PJ, Nyberg L, Pianko S, McHutchinson JG (2000) How often are referred chronic hepatitis C patients candidates for antiviral therapy? Hepatology 32:283A
Cawthorne CH, Rudat KR, Burton MS, Brown KE, Luxon BA, Janney CG, Fimmel CJ (2002) Limited success of HCV antiviral therapy in United States veterans. Am J Gasteroenterol 97:149–155
Muir AJ, Provenzale DA (2002) Descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection. J Clin Gasteroenterol 34:268–271
Yawn BP, Wollan P, Gazzuola L, Kim WR (2002) Diagnosis and 10-year follow-up of a community-based hepatitis C cohort. J Family Pract 51:135–140
Kinzie JL, Naylor PH, Ehrinpreis, MN, Khan N, Sigddiqui FA, Peleman RR, Mutchnick MG (1999) Reluctance of urban clinic patients to undergo treatment with interferon-alpha. Hepatology 30:266A
Butt AA, Wagener M, Shakil AO, Ahmad J (2005) Reasons for non-treatment of hepatitis C in veterans in care. J Viral Hepat 12:81–85
Rosenberg SD, Goodman LA, Osher FC, Swartz MS, Essock SM, Butterfield MI, Constantine NT, Wolford GL, Salyers MP (2001) Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. Am J Public Health 91:31–37
Dieperink E, Ho SB, Thuras P, Willenbring ML (2003) A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 44:104–112
Loftis JM, Socherman RE, Howell CD, Whitehead AJ, Hill JA, Dominitz JA, Hauser P (2004) Association of interferon-alpha-induced depression and improved treatment response in patients with hepatitis C. Neurosci Lett 365:87–91
Raison CL, Broadwell SD, Borisov AS, Manatunga AK, Capuron L, Woolwin BJ, Jacobson IM, Nemeroff CB, Miller AH (2005) Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C. Brain Behav Immun 19:23–27
Straits-Troster KA, Sloan KL, Dominitz JA (2003) Psychiatric and substance use disorder comorbidity with hepatitis C. Psychiatr Ann 33:362–366
Goldsmith RJ, Mindrum G, Myaing M (2003) Psychiatric assessment of patients with hepatitis C virus before initiating interferon treatment. Psychiatr Ann 33:369–376
Loftis JM, Hauser P (2003) Comanagement of depression and HCV treatment. Psychiatr Ann 33:385–391
Fireman M (2003) Hepatitis C treatment and substance use disorders. Psychiatr Ann 33:403–408
Sylvestre DL, Loftis JM, Hauser P, Genser S, Cesari H, Borek N, Kresina TF, Seef L, Francis H (2004) Co-occurring hepatitis C, substance use, and psychiatric illness: treatment issues and developing integrated models of care. J Urban Health 81:719–734
Kresina TF, Khalsa J, Cesari H, Francis H (2005) Hepatitis C virus infection and substance use: medical management and developing models of integrated care—an introduction. Clin Infect Dis 40:S259–S262
Edlin BR, Kresina TF, Raymond DB, Carden MR, Gourevitch MN, Rich JD, Cheever LW, Cargill VA (2005) Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clin Infect Dis 40:S276–S285
Litwin AH, Soloway I, Gourevitch MN (2005) Integrating services for injection drug users infects with hepatitis C virus with methadone maintenance treatment: challenges and opportunities. Clin Infect Dis 40:S339–S345
Fleming CA, Tumilty S, Murray JE, Nunes D (2005) Challenges in the treatment of patients coinfected with HIV and hepatitis C virus: need for team care. Clin Infect Dis 40:S349–S354
Clanon KA, Mueller JJ, Harank M (2005) Integrating treatment for hepatitis C virus infection into an HIV clinic. Clin Infect Dis 40:S362–S366
Acknowledgments
This research was supported by grant PEG228 from Hoffmann La Roche awarded to Donna M. Evon, and grant K24 DK066144 from the NIDDK to Michael W. Fried.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Evon, D.M., Verma, A., Dougherty, K.A. et al. High Deferral Rates and Poorer Treatment Outcomes for HCV Patients with Psychiatric and Substance Use Comorbidities. Dig Dis Sci 52, 3251–3258 (2007). https://doi.org/10.1007/s10620-006-9669-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-006-9669-0